Alector Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company harnesses insights from human genetics, neuroscience, and immunology to advance an innovative pipeline of therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function in the brain. Key programs include latozinemab, a progranulin-elevating monoclonal antibody previously investigated for frontotemporal dementia due to GRN mutations, and nivisnebart for early Alzheimer's disease, alongside preclinical efforts like AL137, an anti-amyloid beta antibody, AL050, a GCase enzyme replacement therapy for Parkinson's and Lewy body dementia, and others targeting tau, alpha-synuclein, and NLRP3. Alector employs its proprietary Alector Brain Carrier technology to enhance blood-brain barrier penetration for these immuno-neurology therapies. Founded in 2013 and headquartered in South San Francisco, California, Alector Inc. plays a significant role in addressing unmet needs in neurodegeneration treatment through genetically validated approaches.